• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Basic research for the development of therapeutic drugs for Alzheimer's disease targeting a novel ubiquitin ligase

Research Project

Project/Area Number 18K06855
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 48020:Physiology-related
Research InstitutionKochi University

Principal Investigator

Yasukawa Takashi  高知大学, 教育研究部医療学系基礎医学部門, 助教 (60291936)

Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Keywordsアルツハイマー病 / ユビキチンリガーゼ / NRBP1 / BRI2 / BRI3 / アミロイドβ
Outline of Final Research Achievements

Alzheimer's disease (AD) is a progressive neurodegenerative disease caused by accumulations of Aβpeptides. Production and fibrillation of Aβ are downregulated by BRI2 and BRI3, which are physiological inhibitors of amyloid precursor protein (APP) processing and Aβ oligomerization. We identify nuclear receptor binding protein 1 (NRBP1) as a substrate receptor of a Cullin-RING ubiquitin ligase (CRL) that targets BRI2 and BRI3 for degradation. Furthermore,NRBP1 knockdown in neuronal cells results in an increase in the abundance of BRI2 and BRI3 and significantly reduces Aβ production. Thus, disrupting interactions between NRBP1 and its substrates BRI2 and BRI3 may provide a useful therapeutic strategy for AD.
We therefore set out to develop a screening system for the discovery of inhibitors.

Academic Significance and Societal Importance of the Research Achievements

まだ詳細な機能がよく分かっていないNRBP1が、基質認識タンパク質として2量体化してCul2ならびにCul4Aと結合してヘテロ2量体型のユビキチンリガーゼ複合体を形成、抗アルツハイマー病因子であるBRI2/BRI3を選択的にユビキチン化して分解に導くことを明らかにした。そして、NRBP1-ユビキチンリガーゼと基質BRI2/BRI3間の相互作用を阻害する化合物が、細胞内BRI2/BRI3のタンパク質量を増加させることで両因子のもつ抗AD作用を増強する新規アルツハイマー病治療薬になり得る可能性があることを示した。

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (4 results)

All 2020 2019 Other

All Journal Article (1 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 1 results,  Open Access: 1 results) Remarks (2 results) Patent(Industrial Property Rights) (1 results)

  • [Journal Article] NRBP1-Containing CRL2/CRL4A Regulates Amyloid β Production by Targeting BRI2 and BRI3 for Degradation2020

    • Author(s)
      Yasukawa T, Tsutsui A, Tomomori-Sato C, Sato S, Saraf A, Washburn MP, Florens L, Terada T, Shimizu K, Conaway RC, Conaway JW, Aso T.
    • Journal Title

      Cell Reports

      Volume: 30 Issue: 10 Pages: 3478-3491

    • DOI

      10.1016/j.celrep.2020.02.059

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Remarks] 講座紹介 遺伝子機能解析学

    • URL

      http://www.kochi-ms.ac.jp/html/gakubu/fg_chmst.html

    • Related Report
      2019 Research-status Report
  • [Remarks] アルツハイマー病創薬への応用が期待される新たな酵素複合体を発見

    • URL

      http://www.kochi-ms.ac.jp/html/news/2019/functionalgenomics2019-1.html

    • Related Report
      2019 Research-status Report
  • [Patent(Industrial Property Rights)] 認知症治療薬のスクリーニング方法2019

    • Inventor(s)
      麻生 悌二郎、安川 孝史
    • Industrial Property Rights Holder
      麻生 悌二郎、安川 孝史
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2019-088444
    • Filing Date
      2019
    • Related Report
      2019 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi